Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23815725 | 0.82 | SHMT2 (0.39) | ALDH1A1SMN1; SMN2ATAD2CYP1A2GAA | |
| SCHEMBL23682669 | 0.77 | GFER (0.36) | ALDH1A1SMN1; SMN2ATAD2CYP1A2GAA | |
| SCHEMBL10176188 | 0.68 | CYP1A2 (0.33) | ALDH1A1SMN1; SMN2CYP1A2GAACYP2C9 | |
| SCHEMBL17865363 | 0.66 | HCRTR2 (0.38) | ALDH1A1CYP1A2GAACYP2C9RXFP1 | |
| SCHEMBL12292842 | 0.66 | COPS5 (0.44) | ALDH1A1SMN1; SMN2CYP1A2GAA | |
| SCHEMBL23815751 | 0.66 | GFER (0.36) | ALDH1A1GAA | |
| SCHEMBL25697722 | 0.64 | GFER (0.33) | ALDH1A1 | |
| SCHEMBL1845956 | 0.63 | PIK3CA (0.45) | ALDH1A1SMN1; SMN2CYP1A2GAA | |
| SCHEMBL14534656 | 0.61 | MEN1 (0.34) | ALDH1A1SMN1; SMN2CYP1A2GAA | |
| SCHEMBL2880579 | 0.61 | COPS5 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | DMPK, DTYMK, MYCBP | ALDH1A1 4368/4885SMN1; SMN2 91/4885ATAD2 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.